Transactions


has sold a minority interest to

has sold a minority interest to

Financial advisor to Leerink Swann & Company

July 2007

Freeman & Co. Acted as Financial Advisor to Leerink Swann & Company, LLC
Date
July 2007
Industry
Broker-Dealer, Private Equity
Transaction
Capital Raise

Leerink Swann receives commitment for investments from Lovell Minnick Partners and the March Group

July 23, 2007 (Boston, MA) – Leerink Swann, the leading healthcare investment bank, today announced that it has entered into a definitive agreement to receive a $35 million minority investment from Lovell Minnick Partners (“Lovell Minnick”) and the March Group (“March”).

Lovell Minnick, a private equity firm that specializes in the global financial services industry, and March, a firm focused primarily on the pharmaceutical and financial services sectors, will have representatives from each firm join Leerink Swann’s Board of Directors. The transaction is expected to close in the third quarter of this year, pending regulatory and shareholder approvals.

“We are pleased to have Lovell Minnick and March join us as shareholders,” stated Jeffrey A. Leerink, Chairman and CEO of Leerink Swann. “Both firms possess deep industry knowledge and company-building expertise. Their representation will add significant value to our Board of Directors as we accelerate our investment banking and advisory businesses and expand into principal and asset management activities.”

Mr. Leerink continued, “The marketplace continues to acknowledge the value of our business model, as evidenced by the Firm’s record revenue and earnings momentum. This investment capital, applied to our unique business platform, will serve as an additional catalyst for Leerink Swann’s aggressive growth plans.”

Jeffrey D. Lovell, Managing Director of Lovell Minnick Partners said, “Leerink Swann has created a tremendous opportunity to capitalize on its industry leading position in healthcare. The Firm’s knowledge focus, driven by its proprietary MEDA Corp network, delivers a sustainable advantage in a highly competitive marketplace. We look forward to supporting them in their efforts.”

Johannes Frey, Chief Operating and Financial Officer of the March Group, continued, “Leerink Swann represents a perfect strategic fit for March. Leerink Swann’s commitment to establishing a world-class investment banking capability geared exclusively toward the healthcare industry ideally positions the Firm to capitalize on one of the largest industries in the global economy.”

Mr. Leerink concluded, “The recognition of Leerink Swann’s differentiated platform by Lovell Minnick and March further enhances our position as the leading healthcare investment bank.”